5-FLUOROURACIL INCORPORATION INTO RNA OF A RAT-LIVER ADENOCARCINOMA AFTER HEPATIC-ARTERY INJECTION TOGETHER WITH DEGRADABLE STARCH MICROSPHERES

被引：5
作者：
TEDER, H
ERICHSEN, C
CHRISTENSSON, PI
JONSSON, PE
STENRAM, U
机构：
[1] LUNDS LASARETT,DEPT SURG,S-22185 LUND,SWEDEN
[2] LUNDS LASARETT,DEPT PATHOL,S-22185 LUND,SWEDEN
来源：
CANCER DRUG DELIVERY | 1987年 / 4卷 / 03期
关键词：
D O I：
10.1089/cdd.1987.4.169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：169 / 176
页数：8
相关论文
共 49 条
[41]   PHASE-II STUDY OF HEPATIC-ARTERY INFUSION WITH 5-FLUOROURACIL, ADRIAMYCIN, AND MITOMYCIN-C (FAM) IN LIVER METASTASES FROM COLORECTAL-CARCINOMA [J].
WILS, J ;
SCHLANGEN, J ;
NAUS, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (03) :215-217
[42]   LIVER TOXICITY OF IONIC (DIATRIZOATE) AND NON-IONIC (C-29) CONTRAST MATERIALS - EFFECTS OF SERUM ENZYMES AFTER HEPATIC-ARTERY INJECTION IN THE RAT [J].
MARE, K ;
ALMEN, T ;
LINDELL, B .
INVESTIGATIVE RADIOLOGY, 1980, 15 (06) :502-506
[43]   TREATMENT OF LIVER METASTASES FROM COLORECTAL-CANCER WITH HEPATIC-ARTERY OCCLUSION, INTRAPORTAL 5-FLUOROURACIL INFUSION, AND ORAL ALLOPURINOL - A RANDOMIZED CLINICAL-TRIAL (VOL 74, PG 2749, 1994) [J].
HAFSTROM .
CANCER, 1995, 75 (05) :1218-1218
[44]   First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228) [J].
Levi, Francis ;
Ducreux, Michel ;
Hebbar, Mohamed ;
Rougier, Philippe ;
Focan, C. N. J. ;
Guimbaud, Rosine ;
Carvalho, Carlos ;
Tumolo, Salvatore ;
Innominato, Pasquale F. ;
Ajavon, Yves ;
Castaing, Denis ;
De Baere, Thierry ;
Karaboue, Abdoulaye ;
Lepere, Celine ;
Boige, Valerie ;
Proux, Laetitia ;
Adam, Rene ;
Bouchahda, Mohamed .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[45]   Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II OPTILIV) [J].
Bouchanda, Mohamed ;
Boige, Valerie ;
Smith, Denis Michel ;
Karaboua, Abdoulaye ;
Hebbar, Mohamed ;
Lepere, Celine ;
Focan, C. N. J. ;
Guimbaud, Rosine ;
Innominato, Pasquale F. ;
Awad, Sameh ;
Carvalho, Carlos ;
Tumolo, Salvatore ;
Truant, Stephanie ;
De Baere, Thierry ;
Castaing, Denis ;
Rougier, Philippe ;
Taieb, Julien ;
Morere, Jean F. ;
Ducreux, Michel ;
Levi, Francis .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46]   Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228). [J].
Levi, Francis ;
Boige, Valerie ;
Hebbar, Mohamed ;
Smith, Denis ;
Lepere, Celine ;
Focan, C. N. J. ;
Guimbaud, Rosine ;
Carvalho, Carlos ;
Tumolo, Salvatore ;
Innominato, Pasquale F. ;
Ajavon, Yves ;
Truant, Stephanie ;
Castaing, Denis ;
De Baere, Thierry ;
Kunstlinger, Francis ;
Karaboue, Abdoulaye ;
Bouchahda, Mohamed ;
Rougier, Philippe R. ;
Adam, Rene ;
Ducreux, Michel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[47]   Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228) [J].
Bouchahda, Mohamed ;
Karaboue, Abdoulaye ;
Etienne-Grimaldi, Marie-Christine ;
Chatelut, Etienne ;
Innominato, Pasquale F. ;
Paintaud, Gilles ;
Ricca, Luana ;
Vibert, Eric ;
Ajavon, Yves ;
Awad, Sameh ;
Castaing, Denis ;
Focan, C. N. J. ;
Milano, Gerard ;
Morere, Jean Francois ;
Adam, Rene ;
Levi, Francis .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[48]   Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228). [J].
Ducreux, Michel ;
Innominato, Pasquale F. ;
Hebbar, Mohamed ;
Smith, Denis Michel ;
Lepere, Celine ;
Focan, C. N. J. ;
Guimbaud, Rosine ;
Carvalho, Carlos ;
Tumolo, Salvatore ;
Awad, Sameh ;
Truant, Stephanie ;
Castaing, Denis ;
Karaboue, Abdoulaye ;
De Baere, Thierry ;
Kunstlinger, Francis ;
Bouchahda, Mohamed ;
Boige, Valerie ;
Rougier, Philippe ;
Adam, Rene ;
Levi, Francis .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[49]   Early tumor shrinkage as a predictor for long-term outcome in patients (pts) with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin plus intravenous Cetuximab (IV-Cet) after failure of one to three systemic protocols (European phase II clinical trial NCT00852228) [J].
Bouchahda, M. ;
Michel, D. ;
Denis, S. ;
Abdoulaye, K. ;
Mohamed, H. ;
Celine, L. ;
Christian, F. ;
Rosine, G. ;
Pasquale, I. ;
Sameh, A. ;
Carlos, C. ;
Salvatore, T. ;
Stephanie, T. ;
Thierry, D. B. ;
Denis, C. ;
Philippe, R. ;
Valerie, B. ;
Francois, M. Jean ;
Rene, A. ;
Francis, L. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 :S348-S348
12345